Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCMNKV)

• Drug Name: MPC-9055 Drug Info
• Synonyms: Vivecon

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMCMNKV

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus GAG protein (HIV gag)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bevirimat	DML2D8Q	Human immunodeficiency virus infection	1C62	Phase 2	[3]
LIPO-5	DMWY0V1	Human immunodeficiency virus infection	1C62	Phase 2	[4]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[5]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[5]
TBC-M4	DM9CDPO	Human immunodeficiency virus infection	1C62	Phase 1	[6]
RVSVIN HIV-1 gag vaccine	DMYRPC8	Human immunodeficiency virus infection	1C62	Phase 1	[7]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[8]
PA-1050040	DMF4KPM	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[9]
Gem 92	DM4ZDVY	Human immunodeficiency virus-1 infection	1C62	Discontinued in Phase 1	[10]
MPI-461359	DMAVD4Q	Human immunodeficiency virus infection	1C62	Terminated	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus GAG protein (HIV gag)	TTFGZB6	GAG_HV1H2	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027745)
• [2] New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087.
• [3] Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
• [4] HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
• [5] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [6] A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
• [7] Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81.
• [8] Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
• [9] US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections.
• [10] Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3.
• [11] Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63.